Work

Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-131230

Authors: Bae P Chu, Neeta Pandit-Taskar, Boglarka Gyurkocza, Qing Liang, Daniel Miodownik, Vijay Reddy, Mark S. Berger, Lawrence T. Dauer

Institutions: Memorial Sloan Kettering Cancer Center, Actinium Pharmaceuticals (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2983871645

Cites:

Cited by:

Related to: 10